About us
The NANOMEDICINE group focuses on the use of nanotechnology for innovative molecular diagnostics and therapeutics. We develop 3D tumor spheroids to optimise combinatory therapy that we validate in our patient-derived tumor organoids.
The group was created in 2003 by Pedro V Baptista at the intersection of Molecular Genetics and Nanotechnology. He has led the group in the field of biofunctionalization of nanoparticles with targeting and silencing moieties and their application in drug delivery and/or gene silencing, in the assessment of toxicology of nanoparticles in in vivo models, in the development of nanobiosensors and microfluidic devices for diagnostic applications, and DNA/RNA biomolecular recognition studies - more.
